15 Years-15 Wishes for 2018 from the Life Raft Group
As we celebrate our 15th year as a non-profit, we at the Life Raft Group would like to share 15 wishes we have for the New Year. Won’t you help us make [...]
As we celebrate our 15th year as a non-profit, we at the Life Raft Group would like to share 15 wishes we have for the New Year. Won’t you help us make [...]
As personalized medicine has become an accepted paradigm, it may be time for oncologists to examine personalized dose levels.In a recent article from Cancer World, the author explores the value of therapeutic drug monitoring for [...]
Saladax Biomedical, a CLIA certified laboratory based in Bethlehem, Pennsylvania, is now providing plasma level testing for imatinib.(Gleevec). Testing is currently free of charge through January 31, 2015, as it is not covered by [...]
Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.
Mutational testing determines whether you have a mutation present in your tumor, and what genotype it is. Examples include Exon 11 or 9 (for KIT positive tumors), Platelet Driven Growth Factor Receptor Alpha (PDGFRA), or [...]
On April 21, 2010, the U.S. Food and Drug Administration (FDA) issued a warning letter to Novartis criticizing its promotion of blood level testing on its CML and GIST Alliance websites. As of September 30, 2010, Novartis terminated the CML and GIST Alliance programs which it had contracted with TDM Pharmaceutical Research, LLC. Since then, the Life Raft Group has been working tirelessly behind the scenes to try and resume this critical testing procedure as it has important potential for managing GIST patient care.
In this article we discuss the importance and relevance of plasma level testing for GIST patients.